Taldefgrobep alfa（Cat No.:I042136）is an investigational protein therapy designed to mimic the effects of erythropoietin, a hormone that stimulates red blood cell production. It works by binding to the erythropoietin receptor (EPOR) on red blood cell precursors in the bone marrow, promoting their growth and maturation. Taldefgrobep alfa is being studied as a potential treatment for anemia, particularly in patients with chronic kidney disease or other conditions that lead to reduced red blood cell production. It is being evaluated in clinical trials to assess its safety, efficacy, and ability to improve hemoglobin levels and reduce the need for blood transfusions.
